Literature DB >> 11508272

Irbesartan normalises the deficiency in glomerular nephrin expression in a model of diabetes and hypertension.

F Bonnet1, M E Cooper, H Kawachi, T J Allen, G Boner, Z Cao.   

Abstract

AIMS/HYPOTHESIS: The location of nephrin has been identified as the slit-diaphragm of the glomerular podocyte. Recent evidence suggests that nephrin could play a key role in the function of the glomerular filtration barrier and the development of proteinuria but its status in long-term diabetes is still not understood. We studied the expression of nephrin in a hypertensive model of diabetic nephropathy and investigated the potential influence of angiotensin II blockade on nephrin gene and protein expression.
METHODS: Streptozotocin-diabetic spontaneously hypertensive rats were given either no treatment or the angiotensin II antagonist, irbesartan, at a dose of 15 mg/kg per day by gavage for 32 weeks. Non-diabetic spontaneously hypertensive rats were used as a control group. Real time RT-PCR and immunohistochemistry were used to assess and quantify gene and protein expression of nephrin.
RESULTS: Diabetic spontaneously hypertensive rats developed albuminuria and had a reduction in both gene and protein expression of nephrin when compared with control rats. Irbesartan treatment prevented the development of albuminuria and completely abrogated the down regulation of nephrin in diabetic rats. CONCLUSION/
INTERPRETATION: Long-term diabetes in spontaneously hypertensive rats is associated with a reduction in both gene and protein expression of nephrin within the kidney. These changes in nephrin levels were completely prevented by angiotensin II antagonist treatment, suggesting a potential novel mechanism to explain the antiproteinuric effect of agents which interrupt the renin-angiotensin system.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11508272     DOI: 10.1007/s001250100546

Source DB:  PubMed          Journal:  Diabetologia        ISSN: 0012-186X            Impact factor:   10.122


  49 in total

Review 1.  Dynamic (re)organization of the podocyte actin cytoskeleton in the nephrotic syndrome.

Authors:  Jun Oh; Jochen Reiser; Peter Mundel
Journal:  Pediatr Nephrol       Date:  2003-12-13       Impact factor: 3.714

Review 2.  Antiproteinuric effect of RAS blockade: new mechanisms.

Authors:  Markus Lassila; Mark E Cooper; Karin Jandeleit-Dahm
Journal:  Curr Hypertens Rep       Date:  2004-10       Impact factor: 5.369

Review 3.  The renin-angiotensin system in glomerular podocytes: mediator of glomerulosclerosis and link to hypertensive nephropathy.

Authors:  Raghu V Durvasula; Stuart J Shankland
Journal:  Curr Hypertens Rep       Date:  2006-05       Impact factor: 5.369

4.  Congenital nephrotic syndrome responsive to angiotensin-converting enzyme inhibition.

Authors:  Rajasree Sreedharan; Detlef Bockenhauer
Journal:  Pediatr Nephrol       Date:  2005-06-18       Impact factor: 3.714

5.  Activation of adenosine 2A receptors preserves structure and function of podocytes.

Authors:  Alaa S Awad; Michael Rouse; Lixia Liu; Amy L Vergis; Diane L Rosin; Joel Linden; John R Sedor; Mark D Okusa
Journal:  J Am Soc Nephrol       Date:  2007-11-28       Impact factor: 10.121

Review 6.  Novel therapeutic approaches for progressive renal disorders by targeting glomerular component mesangial and endothelial cells.

Authors:  Yohei Maeshima
Journal:  Clin Exp Nephrol       Date:  2005-12       Impact factor: 2.801

7.  N-acetyl-seryl-aspartyl-lysyl-proline attenuates renal injury and dysfunction in hypertensive rats with reduced renal mass: council for high blood pressure research.

Authors:  Tang-Dong Liao; Xiao-Ping Yang; Martin D'Ambrosio; Yanlu Zhang; Nour-Eddine Rhaleb; Oscar A Carretero
Journal:  Hypertension       Date:  2009-12-21       Impact factor: 10.190

8.  Renoprotective effects of vasopeptidase inhibition in an experimental model of diabetic nephropathy.

Authors:  B J Davis; C I Johnston; L M Burrell; W C Burns; E Kubota; Z Cao; M E Cooper; T J Allen
Journal:  Diabetologia       Date:  2003-06-28       Impact factor: 10.122

9.  Effects of a new SGLT2 inhibitor, luseogliflozin, on diabetic nephropathy in T2DN rats.

Authors:  Naoki Kojima; Jan M Williams; Teisuke Takahashi; Noriyuki Miyata; Richard J Roman
Journal:  J Pharmacol Exp Ther       Date:  2013-03-14       Impact factor: 4.030

10.  Cannabinoid receptor 1 blockade ameliorates albuminuria in experimental diabetic nephropathy.

Authors:  Federica Barutta; Alessandro Corbelli; Raffaella Mastrocola; Roberto Gambino; Vincenzo Di Marzo; Silvia Pinach; Maria Pia Rastaldi; Paolo Cavallo Perin; Gabriella Gruden
Journal:  Diabetes       Date:  2010-01-12       Impact factor: 9.461

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.